Stay updated with breaking news from Nasdaq Clrb. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Cellectar Biosciences, Inc. (NASDAQ:CLRB – Get Rating) was the target of a significant decline in short interest in May. As of May 15th, there was short interest totalling 81,100 shares, a decline of 7.4% from the April 30th total of 87,600 shares. Currently, 0.9% of the company’s stock are sold short. Based on an average […]
Cellectar Biosciences, Inc. (NASDAQ:CLRB – Get Rating) was the target of a large decrease in short interest in May. As of May 15th, there was short interest totalling 81,100 shares, a decrease of 7.4% from the April 30th total of 87,600 shares. Approximately 0.9% of the shares of the stock are sold short. Based on […]
StockNews.com assumed coverage on shares of Cellectar Biosciences (NASDAQ:CLRB – Get Rating) in a research report released on Wednesday. The firm issued a sell rating on the biopharmaceutical company’s stock. Separately, Oppenheimer dropped their price target on Cellectar Biosciences from $11.00 to $10.00 in a research note on Friday, May 5th. Cellectar Biosciences Trading Up […]
Equities researchers at StockNews.com initiated coverage on shares of Cellectar Biosciences (NASDAQ:CLRB – Get Rating) in a report issued on Wednesday. The brokerage set a “sell” rating on the biopharmaceutical company’s stock. Separately, Oppenheimer cut their price objective on shares of Cellectar Biosciences from $11.00 to $10.00 in a research report on Friday, May 5th. […]
Cellectar Biosciences (NASDAQ: CLRB) recently received a number of ratings updates from brokerages and research firms: 5/24/2023 – Cellectar Biosciences is now covered by analysts at StockNews.com. They set a “sell” rating on the stock. 5/16/2023 – Cellectar Biosciences is now covered by analysts at StockNews.com. They set a “sell” rating on the stock. 5/8/2023 […]